mometasone furoate
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Nasal Polyps
Conditions
Nasal Polyps
Trial Timeline
Jul 1, 2013 → Jan 9, 2018
NCT ID
NCT01616160About mometasone furoate
mometasone furoate is a approved stage product being developed by Merck for Nasal Polyps. The current trial status is terminated. This product is registered under clinical trial identifier NCT01616160. Target conditions include Nasal Polyps.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01616160 | Approved | Terminated |
Competing Products
20 competing products in Nasal Polyps